在大分子药物的发现阶段，传统的候选分子筛选设计主要考虑生物学活性，而较少考虑成药性。那些理化性质不适合成药的分子常常在生产工艺开发时，就会因蛋白纯度低、稳定性差等问题而无法继续推进。所以，将成药性相关的各种因素纳入候选分子筛选考察范畴，可以尽早排除那些具有不希望的化学修饰、易断裂或聚集、表达量过低的蛋白分子，从而避免推进到生产工艺开发阶段时才发现问题，造成大量资源以及时间的浪费。苏州智享拥有一整套大分子成药性研究技术，可提供蛋白理化特性考察、翻译后修饰分析、稳定性评估等服务，帮助研发者缩小筛选范围，锁定那些既具有较高的生物学活性又适合成药的候选分子。

Traditional screening design of candidate molecules is mainly based on biological activity, while pharmaceutical developability is seldom considered at the molecule discovery stage. Those molecules, with physical and chemical properties that are not suitable for pharmaceutical development, are often unable to reach to any result due to low protein purity, poor stability and other problems during the process development. Therefore, by incorporating developability-related factors into the scope of candidate molecule screening, protein molecules with undesirable chemical modifications, easy to fracture or aggregate, or low expression titer can be excluded early on. Otherwise, a large amount of resources and time will be wasted if the problem is not discovered until the production process development stage. IntellectiveBio has a complete set of developability study technologies, including physicochemical properties investigation, post-translational modification analysis, stability assessment etc., to help drug developers narrowing the screening range and targeting the candidate molecules that have both high biological activity and suitable properties for drug development.